Inovio Pharmaceuticals, Inc. (INO) stock
INONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.69+0.06 (+3.68%)
Close on Nov 18, 2026Market cap $174.74MP/E –Yield –
Inovio Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Inovio Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $65.34K, down 70.0% from the year before. Over ten years it grew -47.4% a year on average. The highest annual figure on record is $42.22M in fiscal 2017.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.34K | -70.0% |
| FY2024 | Dec 31, 2024 | $217.76K | -73.8% |
| FY2023 | Dec 31, 2023 | $832.01K | -91.9% |
| FY2022 | Dec 31, 2022 | $10.26M | +478.2% |
| FY2021 | Dec 31, 2021 | $1.77M | -76.1% |
| FY2020 | Dec 31, 2020 | $7.41M | +80.2% |
| FY2019 | Dec 31, 2019 | $4.11M | -86.5% |
| FY2018 | Dec 31, 2018 | $30.48M | -27.8% |
| FY2017 | Dec 31, 2017 | $42.22M | +19.4% |
| FY2016 | Dec 31, 2016 | $35.37M | -12.8% |
| FY2015 | Dec 31, 2015 | $40.57M | +288.0% |
| FY2014 | Dec 31, 2014 | $10.46M | -22.4% |
| FY2013 | Dec 31, 2013 | $13.47M | +227.0% |
| FY2012 | Dec 31, 2012 | $4.12M | -58.0% |
| FY2011 | Dec 31, 2011 | $9.80M | +59.4% |
| FY2010 | Dec 31, 2010 | $6.14M | -32.6% |
| FY2009 | Dec 31, 2009 | $9.12M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $65.34K | – |
| Q4 FY2024 | Dec 31, 2024 | $116.99K | +14.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $100.76K | -55.4% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $102.65K | -17.7% |
| Q3 FY2023 | Sep 30, 2023 | $388.45K | -95.8% |
| Q2 FY2023 | Jun 30, 2023 | $225.97K | -71.2% |
| Q1 FY2023 | Mar 31, 2023 | $114.94K | -42.3% |
| Q4 FY2022 | Dec 31, 2022 | $124.67K | -85.1% |
| Q3 FY2022 | Sep 30, 2022 | $9.15M | +3038.2% |
| Q2 FY2022 | Jun 30, 2022 | $784.40K | +187.5% |
| Q1 FY2022 | Mar 31, 2022 | $199.07K | -46.4% |
| Q4 FY2021 | Dec 31, 2021 | $839.12K | -85.0% |
| Q3 FY2021 | Sep 30, 2021 | $291.70K | +23.5% |
| Q2 FY2021 | Jun 30, 2021 | $272.82K | +2.1% |
| Q1 FY2021 | Mar 31, 2021 | $371.12K | -72.0% |
| Q4 FY2020 | Dec 31, 2020 | $5.58M | +1896.7% |
| Q3 FY2020 | Sep 30, 2020 | $236.18K | -72.8% |
| Q2 FY2020 | Jun 30, 2020 | $267.19K | +96.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.33M | -53.1% |
| Q4 FY2019 | Dec 31, 2019 | $279.49K | -88.8% |
| Q3 FY2019 | Sep 30, 2019 | $866.86K | -56.7% |
| Q2 FY2019 | Jun 30, 2019 | $135.67K | -99.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.83M | +85.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.50M | -71.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.00M | -24.3% |
| Q2 FY2018 | Jun 30, 2018 | $24.45M | +19.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.53M | -85.3% |
| Q4 FY2017 | Dec 31, 2017 | $8.79M | +3.2% |
| Q3 FY2017 | Sep 30, 2017 | $2.64M | -78.9% |
| Q2 FY2017 | Jun 30, 2017 | $20.41M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.51M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.54M | – |
See a number that looks wrong?